Policy & Advocacy

NIGMS invites GSA members to provide suggestions on additional technologies by September 30 that would be useful to biomedical researchers if incorporated into the institute’s programs.

A delay in completing FY 2025 spending bills means federal agencies will not be able to move forward on grant awards for FY 2025 and grant recipients may have to discontinue their activities or find other funding sources until they receive the FY 2025 funding.

The NIH is requesting recommendations from the research community on ways that we can improve the postdoctoral training experience and career progression in the biomedical field.

The resource is meant to assist the research community in understanding how NIH policies guide artificial intelligence (AI)-related research.

FASEB’s comments highlighted the need for more consistent data definitions and collection instruments to understand disability prevalence and impact on life and work in STEM research fields.

The US House and Senate Appropriations Committees will release their proposed funding bills for various federal agencies, including those overseeing biomedical research.

As House spending bills go through subcommittee markups, Senate appropriators laid out 302(b) allocations, despite lack of bi-partisan agreement, to speed up consideration for bills that will impact the NIH and NSF budgets.

Research!America is attempting to lead the assembly of questions from stakeholders that they can bring to Capitol Hill staffers for clarification.

The draft policy updates NIH’s current policy, in effect since 2008, and represents the agency’s continued efforts to implement the White House’s 2022 memorandum, “Ensuring Free, Immediate, and Equitable Access to Federally Funded Research.”

NCBI will update the higher-level classification of birds, budding yeasts, prokaryotes, and Viruses to its Taxonomy resource.

FASEB and the Coalition for Life Sciences cohosted the annual Life Science Fair on Capitol Hill to engage members of Congress and congressional staff about the value of federal investment in the life sciences.